Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
| Business Activity | PASS |
| Debt Ratio (0.81%) | FAIL |
| Cash Ratio (0.17%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | -0.04 | Pending | -- |
| 2026-05-13 | -0.05 | -0.08 | -45.5% |
| 2026-03-25 | -0.05 | -0.09 | -80.0% |
| 2025-11-13 | -0.05 | -0.05 | -7.1% |
| 2025-08-07 | -0.06 | 0.03 | +152.9% |
| 2025-05-14 | -0.07 | -0.02 | +71.4% |
| 2025-03-31 | -0.05 | -0.14 | -162.5% |
| 2024-11-07 | -0.06 | -0.08 | -26.3% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8.9M | -$5.1M | -$3.9M | $6.1M | -$3.0M | -0.08 |
| 2025-12-31 | $9.2M | -$5.5M | -$4.4M | $6.8M | -$3.9M | -0.09 |
| 2025-09-30 | $9.5M | -$3.2M | -$2.5M | $6.7M | -$2.9M | -0.05 |
| 2025-06-30 | $9.6M | $1.9M | $3.0M | $6.8M | -$3.6M | 0.03 |
| 2025-03-31 | $8.7M | -$1.5M | -$469.0K | $6.2M | -$3.9M | -0.02 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2025-11-18 | CHAN PHILLIP P | Chief Executive Officer | 100,000 | $64.0K |
| 2025-08-08 | CAPPONI VINCENT J | President | 89,100 | -- |
| 2025-08-08 | MARIANI PETER J | Chief Financial Officer | 71,500 | -- |
| 2025-08-08 | CHAN PHILLIP P | Chief Executive Officer | 105,600 | -- |
| 2025-08-08 | DELIARGYRIS EFTHYMIOS | Officer | 70,000 | -- |
| 2025-02-24 | CAPPONI VINCENT J | President | 12,000 | $13.6K |
| 2025-02-24 | MARIANI PETER J | Chief Financial Officer | 32,625 | $36.9K |
| 2025-02-24 | CHAN PHILLIP P | Chief Executive Officer | 34,168 | $38.6K |
| 2025-02-24 | SOBEL ALAN D | Director | 21,950 | $24.8K |
| 2025-02-24 | BATOR MICHAEL G. | Director | 10,000 | $11.3K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Avenir Corp | 5.2M | $2.4M | 0.1% |
| Vanguard Capital Management LLC | 1.9M | $866.3K | 0.0% |
| Skylands Capital, LLC | 1.7M | $786.8K | 0.0% |
| Neuberger Berman Group, LLC | 1.7M | $775.5K | 0.0% |
| CM Management, LLC | 1.5M | $680.4K | 0.0% |
| Blackrock Inc. | 783.0K | $360.8K | 0.0% |
| Geode Capital Management, LLC | 707.3K | $325.9K | 0.0% |
| Sargent Investment Group, LLC | 549.9K | $253.4K | 0.0% |
| Pathstone Holdings, LLC | 500.0K | $230.4K | 0.0% |
| Vanguard Fiduciary Trust Co | 313.9K | $144.6K | 0.0% |
$53.4M
13.17
3
$37.2M
$29.3M
3.00
27.78
0.0%
129
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.04 | Pending | — |
| 2026-05-13 | $-0.05 | $-0.08 | -45.5% |
| 2026-03-25 | $-0.05 | $-0.09 | -80.0% |
| 2025-11-13 | $-0.05 | $-0.05 | -7.1% |
| 2025-08-07 | $-0.06 | $0.03 | +152.9% |
| 2025-05-14 | $-0.07 | $-0.02 | +71.4% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($2.88, 2 analysts) | |||
| 10 | $5.71 | +$23.00 (404%) | 28.7R |
| 50 | $28.54 | +$115.00 (404%) | 28.7R |
| 100 | $57.08 | +$230.00 (404%) | 28.7R |
- Elevated short interest (27.78 days to cover)
- Valuation stretched on forward earnings
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| BLLN | 0.232 |
| ADEA | 0.229 |
| CNC | 0.211 |
| MARKAZ.KW | 0.205 |
| TDOC | 0.203 |
| Ticker | Correlation |
|---|---|
| ENGRO.KA | -0.143 |
| 0823EA.KL | -0.143 |
| IAG.AX | -0.138 |
| EMMA | -0.136 |
| ZAINBH.BH | -0.125 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.